Certain Stock Options of Annexon, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2021.
January 19, 2021
Share
Certain Stock Options of Annexon, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2021. These Stock Options will be under lockup for 181 days starting from 23-JUL-2020 to 20-JAN-2021.
Details:
The executive officers, directors, and all of the holders of equity securities have entered into a lock up agreement pursuant to which, they will not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly any shares of common stock or securities convertible into or exchangeable or exercisable for any shares of common stock, or publicly disclose the intention to make any offer, sale, pledge, disposition or 181filing, or enter into any swap, hedging, or other agreement that transfers , in whole or in part, any of the economic consequences associated with the ownership of any shares of common stock or any such other securities in each case without the prior written consent of J.P. Morgan Securities LLC, BofA Securities, Inc. and Cowen and Company, LLC for a period of 180 days after the date of this prospectus.
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.